These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 19758759

  • 1. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [Abstract] [Full Text] [Related]

  • 2. Predicting anthracycline benefit: have we made any progress?
    Moretti E, Oakman C, Di Leo A.
    Curr Opin Oncol; 2009 Nov; 21(6):507-15. PubMed ID: 19713842
    [Abstract] [Full Text] [Related]

  • 3. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 4. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 5. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD.
    Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
    [Abstract] [Full Text] [Related]

  • 6. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z, Lu J.
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anthracycline war: no victor yet.
    Young P.
    J Natl Cancer Inst; 2009 Sep 02; 101(17):1171-3. PubMed ID: 19706625
    [No Abstract] [Full Text] [Related]

  • 11. Topoisomerase 2 alpha and the case for individualized breast cancer therapy.
    Glynn RW, Miller N, Whelan MC, Kerin MJ.
    Ann Surg Oncol; 2010 May 02; 17(5):1392-7. PubMed ID: 20217261
    [Abstract] [Full Text] [Related]

  • 12. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN, Yang L, Tang C, Yang D, Lupu R.
    Clin Cancer Res; 1998 Apr 02; 4(4):1005-12. PubMed ID: 9563896
    [Abstract] [Full Text] [Related]

  • 13. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
    Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z.
    Hum Pathol; 2010 Nov 02; 41(11):1617-23. PubMed ID: 20688355
    [Abstract] [Full Text] [Related]

  • 14. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.
    Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP.
    Eur J Cancer; 2006 Nov 02; 42(17):2954-60. PubMed ID: 16935488
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
    Gennari A, Pronzato P.
    Clin Breast Cancer; 2008 Dec 02; 8 Suppl 4():S179-83. PubMed ID: 19158039
    [Abstract] [Full Text] [Related]

  • 17. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S, Huang L, Liu Y, Chen CM, Wu J, Shao ZM.
    Eur J Surg Oncol; 2013 Jun 02; 39(6):619-26. PubMed ID: 23473851
    [Abstract] [Full Text] [Related]

  • 18. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V, Schiffers J, Kahlert S, Mainka P, Engel J, Kirchner T, Diebold J, Mayr D.
    Diagn Mol Pathol; 2012 Jun 02; 21(2):77-83. PubMed ID: 22555090
    [Abstract] [Full Text] [Related]

  • 19. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T, Takeyoshi I.
    Breast Cancer; 2012 Oct 02; 19(4):309-14. PubMed ID: 21725655
    [Abstract] [Full Text] [Related]

  • 20. Using specific cytotoxics with a targeted mind.
    Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L.
    Breast; 2007 Dec 02; 16 Suppl 2():S120-6. PubMed ID: 17720501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.